Ob/gyns are increasingly being called upon to manage subclinical thyroid disease. In this concluding article of a two-part series, two experts clarify the controversy over when to treat mild hyperthyroidism. Do treat a mildly overactive thyroid in elderly patients, they say, because low bone density and cardiac abnormalities can do substantial harm.
Few colleagues would argue over how to diagnose or treat overt thyroid disease. But it's a different story for more subtle "mild" thyroid disease-a term now commonly preferred to "subclinical."1 A key point from our article on mild hypothyroidism ("When should you screen for and treat mild hypothyroidism?" Contemporary OB/GYN, January 2006) http://www.contemporaryobgyn.net/obgyn/article/articleDetail.jsp?id=283482 holds true for mild hyperthyroidism: Diagnosing and deciding when to treat mild thyroid disease is still complicated by controversies over the reference values of the thyroid function tests upon which we base the diagnosis of disease and many clinical decisions. Once again our goal here is to discuss factors affecting your decision on when to treat mild hyperthyroidism and to give causes, guidelines, and treatment options.
Measuring 'normal' thyroid function
Also as discussed in Part I, when individuals with risk factors for autoimmune thyroid disease (especially thyroid antibodies), were excluded from a large control population, the average TSH was ~1.5 μU/mL.2 The lower limit for TSH in this group, and in other reports, was ~0.4 μU/mL. [Hence, mild hyperthyroidism may be defined by a TSH below 0.4 μU/mL with normal thyroid hormone levels (free T4 and T3). However, patients with mild hyperthyroidism are often divided further into two subgroups, one with a TSH of 0.1 to 0.4, and a second group with TSH under 0.1. With third-generation TSH assays, TSH may be reported at levels below 0.1, and this clearly indicates hyperthyroidism.]
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More